Systematic review / meta-analysis / 2005
Glucosamine improved osteoarthritis pain and function in pooled RCTs, though benefits were not seen in studies with adequate allocation concealment.
A systematic review and meta-analysis of 20 RCTs evaluated the efficacy and safety of glucosamine in 2,570 osteoarthritis patients. Overall, glucosamine outperformed placebo with a 28% improvement in pain (SMD -0.61, 95% CI -0.95 to -0.28) and a 21% improvement in Lequesne function (SMD -0.51, 95% CI -0.96 to -0.05), but WOMAC pain, function, and stiffness did not reach statistical significance. Analysis restricted to eight studies with adequate allocation concealment failed to show benefit for pain or WOMAC function. Benefits were observed in trials using the Rotta preparation, whereas non-Rotta preparations did not achieve statistically significant improvements in pain or WOMAC function. Glucosamine was as safe as placebo regarding adverse reactions (RR 0.97, 95% CI 0.88 to 1.08).
- Study type
- Systematic review and meta-analysis of RCTs
- Who was studied
- 2,570 patients with osteoarthritis across 20 randomized controlled trials
- What was measured
- Pain, functional impairment (Lequesne and WOMAC indices), stiffness, radiological progression, and adverse reactions
THE PAPER
Glucosamine therapy for treating osteoarthritis.
Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, Hochberg MC, Wells G. Cochrane Database Syst Rev, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.